Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).

Condition or disease

Intervention/treatment

Phase

HIV Infections

Drug: EfavirenzDrug: LamivudineDrug: Stavudine

Phase 3

Detailed Description:

Patients are randomized to receive blinded stavudine extended release (d4T ER) or immediate release (d4T IR) formulation. Randomization is balanced by screening HIV viral load of less than 30,000 copies/ml or at least 30,000 copies/ml and by site. Patients also receive open-label efavirenz (EFV) and lamivudine (3TC). Efficacy is evaluated over 48 weeks of the dosing period and safety is evaluated over the entire dosing period (56 weeks).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

12 Years and older (Child, Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

Are at least 18 years old. Patients living in USA, Puerto Rico, Australia, Brazil, Singapore, and Thailand can be at least 12 years old (need consent of parent or guardian if under 18).

Have a viral load of at least 2,000 copies/ml within 21 days of study entry.

Have a CD4 count of at least 100 cells/mm3 within 21 days of study entry.

Agree to use a barrier method of birth control (such as condoms) during the study.

Are available for follow-up for at least 56 weeks.

Exclusion Criteria

Patients will not be eligible for this study if they:

Are pregnant or breast-feeding.

Have taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) for more than 30 days and within 14 days of study entry.

Have a new opportunistic (HIV-related) infection or condition requiring treatment.

Have acute (early) HIV infection.

Have diarrhea (at least 6 loose stools/day for at least 7 days in a row) within 30 days prior to study entry.

Abuse alcohol or drugs.

Have active hepatitis within 30 days prior to study entry.

Have a history of peripheral neuropathy (a condition affecting the nervous system).

Cannot take medications by mouth.

Are allergic to certain antiviral drugs.

Need to take certain medications that should not be taken with EFV.

Have certain other conditions or prior treatments that might affect the study.